(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
24 August 2006 (24.08.2006)

PCT

(10) International Publication Number
WO 2006/087316 A1

(51) International Patent Classification:
A61K 31/573 (2006.01) *A61P 11/06* (2006.01)
A61K 31/46 (2006.01)

(21) International Application Number:
PCT/EP2006/050901

(22) International Filing Date:
13 February 2006 (13.02.2006)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
05003275.4 16 February 2005 (16.02.2005) EP

(71) Applicant *(for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BF, BG, BJ, BR, BW, BY, BZ, CA, CF, CG, CH, CI, CM, CN, CO, CR, CU, CY, CZ, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GA, GB, GD, GE, GH, GM, GN, GQ, GR, GW, HR, HU, ID, IE, IL, IN, IS, IT, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MC, MD, MG, MK, ML, MN, MR, MW, MX, MZ, NA, NE, NG, NI, NL, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE only)*: **BOEHRINGER INGELHEIM INTERNATIONAL GMBH** [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(71) Applicant *(for DE only)*: **BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG** [DE/DE]; Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(72) Inventor; and

(75) Inventor/Applicant *(for US only)*: **PIEPER, Michael, P.** [DE/DE]; Geschwister-scholl-str. 45, 88400 Biberach (DE).

(74) Agents: **HAMMANN, Heinz** et al.; Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Strasse 173, 55216 Ingelheim Am Rhein (DE).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PHARMACEUTICAL COMPOSITIONS COMPRISING ANTICHOLINERGICS AND ETIPREDNOL

(57) Abstract: The present invention relates to novel pharmaceutical compositions based on anticholinergics and etiprednol, processes for preparing them and their use in the treatment of respiratory diseases.

WO 2006/087316 A1

PHARMACEUTICAL COMPOSITIONS COMPRISING ANTICHOLINERGICS AND ETIPREDNOL

The present invention relates to novel pharmaceutical compositions based on anticholinergics and etiprednol, processes for preparing them and their use in the treatment of respiratory diseases.

Description of the invention


The present invention relates to novel pharmaceutical compositions based on anticholinergics and etiprednol, processes for preparing them and their use in the treatment of respiratory diseases.

Surprisingly, an unexpectedly beneficial therapeutic effect can be observed in the treatment of inflammatory or obstructive diseases of the respiratory tract if one or more anticholinergics are used together with the corticosteroid Etiprednol. In view of this beneficial effect the pharmaceutical combinations according to the invention can be used in smaller doses than would be the case with the individual compounds used in monotherapy in the usual way. This reduces unwanted side effects such as may occur when corticosteroids are administered, for example.

The effects mentioned above may be observed both when the two active substances are administered simultaneously in a single active substance formulation and when they are administered successively in separate formulations. According to the invention, it is preferable to administer the active substance ingredients simultaneously in a single formulation.

By the salts **1** which may be used within the scope of the present invention are meant the compounds which contain, in addition to tiotropium, oxitropium or ipratropium, as counter-ion (anion), chloride, bromide, iodide, sulphate, methanesulphonate or para-toluenesulphonate. Within the scope of the present invention, the methanesulphonate, chloride, bromide and iodide are preferred of all the salts **1**, the methanesulphonate and bromide being of particular importance. Of outstanding importance according to the invention are salts **1** selected from among tiotropium bromide, oxitropium bromide and ipratropium bromide. Tiotropium bromide is particularly preferred, preferably in the form of its crystalline monohydrate as disclosed in WO 02/30928 A1.


In another preferred embodiment the anticholinergic **1** is selected from the compounds of formula **1a**



1a

wherein

A denotes a double-bonded group selected from among



;

X^- may have the meanings as mentioned hereinbefore, preferably chloride, bromide or methansulphonate,

R^1 and R^2 which may be identical or different denote a group selected from among methyl, ethyl, n-propyl and iso-propyl, which may optionally be substituted by hydroxy or fluorine, preferably unsubstituted methyl;

R^3, R^4, R^5 and R^6, which may be identical or different, denote hydrogen, methyl, ethyl,

methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF_3 or NO_2;

R^7 denotes hydrogen, methyl, ethyl, methyloxy, ethyloxy, $-CH_2-F$, $-CH_2-CH_2-F$, $-O-CH_2-F$, $-O-CH_2-CH_2-F$, $-CH_2-OH$, $-CH_2-CH_2-OH$, CF_3, $-CH_2-OMe$, $-CH_2-CH_2-OMe$, $-CH_2-OEt$, $-CH_2-CH_2-OEt$, -O-COMe, -O-COEt, $-O-COCF_3$, $-O-COCF_3$, fluorine, chlorine or bromine,

optionally together with a pharmaceutically acceptable excipient.

The compounds of formula **1a** are known in the art (WO 02/32899).

In a preferred embodiment of the invention the method comprises administration of compounds of formula **1a**, wherein

X^- denotes bromide;

R^1 and R^2 which may be identical or different denote a group selected from methyl and ethyl, preferably methyl;


R^3, R^4, R^5 and R^6, which may be identical or different, denote hydrogen, methyl, methyloxy, chlorine or fluorine;

R^7 denotes hydrogen, methyl or fluorine,


optionally together with a pharmaceutically acceptable excipient.

Of particular importance within the method according to the invention are compounds of general formula **1a**, wherein

A denotes a double-bonded group selected from among



and




The compounds of formula **1a**, may optionally be administered in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.

Of particular importance within the method according to the invention are the following compounds of formula **1a**:

- tropenol 2,2-diphenylpropionic acid ester methobromide,
- scopine 2,2-diphenylpropionic acid ester methobromide,
- scopine 2-fluoro-2,2-diphenylacetic acid ester methobromide and
- tropenol 2-fluoro-2,2-diphenylacetic acid ester methobromide.

In a yet another preferred embodiment the anticholinergic **1** is selected from the compounds of formula **1b**



1b

wherein

A, X^-, R^1 and R^2 may have the meanings as mentioned hereinbefore and wherein


R^7, R^8, R^9, R^{10}, R^{11} and R^{12} , which may be identical or different, denote hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF_3 or NO_2, with the proviso that at least one of the groups R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is not hydrogen,

optionally together with a pharmaceutically acceptable excipient.


The compounds of formula **1b** are known in the art (WO 02/32898).

In a preferred embodiment of the invention the method comprises administration of compounds of formula **1b**, wherein

A denotes a double-bonded group selected from among



and



;

X^- denotes bromide;

R^1 and R^2 which may be identical or different denote methyl or ethyl, preferably methyl;

R^7, R^8, R^9, R^{10}, R^{11} and R^{12}, which may be identical or different, denote hydrogen, fluorine, chlorine or bromine, preferably fluorine with the proviso that at least one of the groups R^7, R^8, R^9, R^{10}, R^{11} and R^{12} not hydrogen,


optionally together with a pharmaceutically acceptable excipient.

Of particular importance within the method according to the invention are the following compounds of formula **1b**:

- tropenol 3,3',4,4'-tetrafluorobenzilic acid ester methobromide,
- scopine 3,3',4,4'-tetrafluorobenzilic acid ester methobromide,
- scopine 4,4'-difluorobenzilic acid ester methobromide,
- tropenol 4,4'-difluorobenzilic acid ester methobromide,
- scopine 3,3'-difluorobenzilic acid ester methobromide, and
- tropenol 3,3'-difluorobenzilic acid ester methobromide.

The pharmaceutical compositions according to the invention may contain the compounds of formula **1b** optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.

In a yet another preferred embodiment the anticholinergic **1** is selected from the compounds of formula **1c**



1c

wherein A and X^- may have the meanings as mentioned hereinbefore, and wherein

R^{15} denotes hydrogen, hydroxy, methyl, ethyl, $-CF_3$, CHF_2 or fluorine;

$R^{1'}$ and $R^{2'}$ which may be identical or different denote C_1-C_5-alkyl which may optionally be substituted by C_3-C_6-cycloalkyl, hydroxy or halogen,

or

$R^{1'}$ and $R^{2'}$ together denote a $-C_3$-C_5-alkylene-bridge;


R^{13}, R^{14}, $R^{13'}$ and $R^{14'}$ which may be identical or different denote hydrogen, $-C_1$-C_4-alkyl, $-C_1$-C_4-alkyloxy, hydroxy, $-CF_3$, $-CHF_2$, CN, NO_2 or halogen,

optionally together with a pharmaceutically acceptable excipient.

The compounds of formula **1c** are known in the art (WO 03/064419).

In a preferred embodiment of the invention the method comprises administration of compounds of formula **1c**, wherein

A denotes a double-bonded group selected from among



;

X^- denotes an anion selected from among chloride, bromide and methanesulphonate, preferably bromide;

R^{15} denotes hydroxy, methyl or fluorine, preferably methyl or hydroxy;



$R^{1'}$ and $R^{2'}$ which may be identical or different represent methyl or ethyl, preferably methyl;

R^{13}, R^{14}, $R^{13'}$ and $R^{14'}$ which may be identical or different represent hydrogen, $-CF_3$, $-CHF_2$ or fluorine, preferably hydrogen or fluorine,

optionally together with a pharmaceutically acceptable excipient.

In another preferred embodiment of the invention the method comprises administration of compounds of formula **1c**, wherein

A denotes a double-bonded group selected from among


and

;

X^- denotes bromide;

R^{15} denotes hydroxy or methyl, preferably methyl;

$R^{1'}$ and $R^{2'}$ which may be identical or different represent methyl or ethyl, preferably methyl;

R^{13}, R^{14}, $R^{13'}$ and $R^{14'}$ which may be identical or different represent hydrogen or fluorine,


optionally together with a pharmaceutically acceptable excipient.

Of particular importance within the method according to the invention are the following compounds of formula **1c**:

- tropenol 9-hydroxy-fluorene-9-carboxylate methobromide ;
- tropenol 9-fluoro-fluorene-9-carboxylate methobromide ;
- scopine 9-hydroxy-fluorene-9-carboxylate methobromide ;
- scopine 9-fluoro-fluorene-9-carboxylate methobromide ;
- tropenol 9-methyl-fluorene-9-carboxylate methobromide ;
- scopine 9-methyl-fluorene-9-carboxylate methobromide .

The pharmaceutical compositions according to the invention may contain the compounds of formula **1c** optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.

In a yet another preferred embodiment the anticholinergic **1** is selected from the compounds of formula **1d**



1d

wherein X^- may have the meanings as mentioned hereinbefore, and wherein

D and B which may be identical or different, preferably identical, denote -O, -S, -NH, $-CH_2$, -CH=CH, or $-N(C_1\text{-}C_4\text{-alkyl})$-;

R^{16} denotes hydrogen, hydroxy, $-C_1\text{-}C_4$-alkyl, $-C_1\text{-}C_4$-alkyloxy,

-C_1-C_4-alkylene-Halogen, -O-C_1-C_4-alkylene-halogen, -C_1-C_4-alkylene-OH, -CF_3, CHF_2, -C_1-C_4-alkylene-C_1-C_4-alkyloxy, -O-COC_1-C_4-alkyl, -O-COC_1-C_4-alkylene-halogen, -C_1-C_4-alkylene-C_3-C_6-cycloalkyl, -O-$COCF_3$ or halogen;

$R^{1"}$ and $R^{2"}$ which may be identical or different, denote -C_1-C_5-alkyl, which may optionally be substituted by -C_3-C_6-cycloalkyl, hydroxy or halogen, or
$R^{1"}$ and $R^{2"}$ together denote a -C_3-C_5-alkylene bridge;

R^{17}, R^{18}, $R^{17'}$ and $R^{18'}$, which may be identical or different, denote hydrogen, C_1-C_4-alkyl, C_1-C_4-alkyloxy, hydroxy, -CF_3, -CHF_2, CN, NO_2 or halogen;

R^X and $R^{X'}$ which may be identical or different, denote hydrogen, C_1-C_4-alkyl, C_1-C_4-alkyloxy, hydroxy, -CF_3, -CHF_2, CN, NO_2 or halogen
or
R^X and $R^{X'}$ together denote a single bond or a bridging group selected from among the bridges -O, -S, -NH, -CH_2, -CH_2-CH_2-, -N(C_1-C_4-alkyl), -CH(C_1-C_4-alkyl)- and -C(C_1-C_4-alkyl)$_2$,

optionally together with a pharmaceutically acceptable excipient.

The compounds of formula **1d** are known in the art (WO 03/064418).

In another preferred embodiment of the invention the method comprises administration of compounds of formula **1d** wherein

X^- denotes chloride, bromide, or methanesulphonate, preferably bromide;

D and B which may be identical or different, preferably identical, denote -O, -S, -NH or -CH=CH-;

R^{16} denotes hydrogen, hydroxy, -C_1-C_4-alkyl, -C_1-C_4-alkyloxy, -CF_3, -CHF_2, fluorine, chlorine or bromine;

$R^{1"}$ and $R^{2"}$ which may be identical or different, denote C_1-C_4-alkyl, which may optionally be substituted by hydroxy, fluorine, chlorine or bromine, or
$R^{1"}$ and $R^{2"}$ together denote a -C_3-C_4-alkylene-bridge;

R^{17}, R^{18}, $R^{17'}$ and $R^{18'}$, which may be identical or different, denote hydrogen, C1-C4-alkyl, C1-C4-alkyloxy, hydroxy, -CF3, -CHF2, CN, NO2, fluorine, chlorine or bromine;

R^X and $R^{X'}$ which may be identical or different, denote hydrogen, C_1-C_4-alkyl, C_1-C_4-alkyloxy, hydroxy, -CF_3, -CHF_2, CN, NO_2, fluorine, chlorine or bromine
or

R^X and $R^{X'}$ together denote a single bond or a bridging group selected from among the bridges -O, -S, -NH- and $-CH_2-$,

optionally together with a pharmaceutically acceptable excipient.

In another preferred embodiment of the invention the method comprises administration of compounds of formula **1d**, wherein

X^-	denotes chloride, bromide, or methanesulphonate, preferably bromide;
D and B	which may be identical or different, preferably identical, denote -S or -CH=CH-;
R^{16}	denotes hydrogen, hydroxy or methyl;
$R^{1"}$ and $R^{2"}$	which may be identical or different, denote methyl or ethyl;
R^{17}, R^{18}, $R^{17'}$	and $R^{18'}$, which may be identical or different, denote hydrogen, $-CF_3$ or fluorine, preferably hydrogen;
R^X and $R^{X'}$	which may be identical or different, denote hydrogen, $-CF_3$ or fluorine, preferably hydrogen or
	R^X and $R^{X'}$ together denote a single bond or the bridging group -O-,

optionally together with a pharmaceutically acceptable excipient.

In another preferred embodiment of the invention the method comprises administration of compounds of formula **1d,** wherein

X^-	denotes bromide;
D and B	denote -CH=CH-;
R^{16}	denotes hydrogen, hydroxy or methyl;
$R^{1"}$ and $R^{2"}$	denote methyl;
R^{17}, R^{18}, $R^{17'}$	and $R^{18'}$, which may be identical or different, denote hydrogen or fluorine, preferably hydrogen;
R^X and $R^{X'}$	which may be identical or different, denote hydrogen or fluorine, preferably hydrogen or
	R^X and $R^{X'}$ together denote a single bond or the bridging group -O-,

optionally together with a pharmaceutically acceptable excipient.


Of particular importance within the method according to the invention are the following compounds of formula **1d**:

- cyclopropyltropine benzilate methobromide;
- cyclopropyltropine 2,2-diphenylpropionate methobromide;
- cyclopropyltropine 9-hydroxy-xanthene-9-carboxylate methobromide;
- cyclopropyltropine 9-methyl-fluorene-9-carboxylate methobromide;
- cyclopropyltropine 9-methyl-xanthene-9-carboxylate methobromide;

- cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide ;
- cyclopropyltropine methyl 4,4'-difluorobenzilate methobromide.

The pharmaceutical compositions according to the invention may contain the compounds of formula **1d** optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.



In a yet another preferred embodiment the anticholinergic **1** is selected from the compounds of formula **1e**



1e

wherein X^- may have the meanings as mentioned hereinbefore, and wherein

A' denotes a double-bonded group selected from among

 and  ;

R^{19} denotes hydroxy, methyl, hydroxymethyl, ethyl, $-CF_3$, CHF_2 or fluorine;

$R^{1'''}$ and $R^{2'''}$ which may be identical or different denote C_1-C_5-alkyl which may optionally be substituted by C_3-C_6-cycloalkyl, hydroxy or halogen,
or
$R^{1'''}$ and $R^{2'''}$ together denote a -C_3-C_5-alkylene-bridge;

R^{20}, R^{21}, $R^{20'}$ and $R^{21'}$ which may be identical or different denote hydrogen, -C_1-C_4-alkyl, -C_1-C_4-alkyloxy, hydroxy, $-CF_3$, $-CHF_2$, CN, NO_2 or halogen,



optionally together with a pharmaceutically acceptable excipient.

The compounds of formula **1e** are known in the art (WO 03/064417).

In another preferred embodiment of the invention the method comprises administration of compounds of formula **1e** wherein

A' denotes a double-bonded group selected from among

10

 and  ;

X^- denotes chloride, bromide or methanesulphonate, preferably bromide;

R^{19} denotes hydroxy or methyl;



$R^{1'''}$ and $R^{2'''}$ which may be identical or different represent methyl or ethyl, preferably methyl;

R^{20}, R^{21}, $R^{20'}$ and $R^{21'}$ which may be identical or different represent hydrogen, $-CF_3$, $-CHF_2$ or fluorine, preferably hydrogen or fluorine,

optionally together with a pharmaceutically acceptable excipient.

In another preferred embodiment of the invention the method comprises administration of compounds of formula **1e** wherein

A' denotes a double-bonded group selected from among

 and  ;

X^- denotes bromide;

R^{19} denotes hydroxy or methyl, preferably methyl;

$R^{1'''}$ and $R^{2'''}$ which may be identical or different represent methyl or ethyl, preferably methyl;


R^3, R^4, $R^{3'}$ and $R^{4'}$ which may be identical or different represent hydrogen or fluorine, optionally together with a pharmaceutically acceptable excipient.

Of particular importance within the method according to the invention are the following compounds of formula **1e**:


- tropenol 9-hydroxy-xanthene-9-carboxylate methobromide ;
- scopine 9-hydroxy-xanthene-9-carboxylate methobromide ;
- tropenol 9-methyl-xanthene-9-carboxylate methobromide ;
- scopine 9-methyl-xanthene-9-carboxylate methobromide ;
- tropenol 9-ethyl-xanthene-9-carboxylate methobromide ;
- tropenol 9-difluoromethyl-xanthene-9-carboxylate methobromide ;
- scopine 9-hydroxymethyl-xanthene-9-carboxylate methobromide .

The pharmaceutical compositions according to the invention may contain the compounds of formula **1e** optionally in the form of the individual optical isomers, mixtures of the individual enantiomers or racemates thereof.


Within the scope of the present invention the term anticholinergics **1** denotes salts which are preferably selected from among tiotropium salts, oxitropium salts and ipratropium salts, most preferably tiotropium salts. In the above-mentioned salts the cations tiotropium, oxitropium and ipratropium are the pharmacologically active ingredients. Within the scope of the present patent application, an explicit reference to the above cations is indicated by the use of the number **1'** or the cations of the following formulae




1a';




1b'



1c';



1d';



or **1e'**.

Any reference to compounds **1** naturally also includes a reference to the ingredients **1'**.

The alkyl groups used, unless otherwise stated, are branched and unbranched alkyl groups having 1 to 5 carbon atoms. Examples include: methyl, ethyl, propyl or butyl. The groups methyl, ethyl, propyl or butyl may optionally also be referred to by the abbreviations Me, Et, Prop or Bu. Unless otherwise stated, the definitions propyl and butyl also include all possible isomeric forms of the groups in question. Thus, for example, propyl includes n-propyl and iso-propyl, butyl includes iso-butyl, sec. butyl and tert.-butyl, etc.

The cycloalkyl groups used, unless otherwise stated, are alicyclic groups with 3 to 6 carbon atoms. These are the cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl groups. According to the invention cyclopropyl is of particular importance within the scope of the present invention.

The alkylene groups used, unless otherwise stated, are branched and unbranched double-bonded alkyl bridges with 1 to 5 carbon atoms. Examples include: methylene, ethylene, propylene or butylene.

The alkylene-halogen groups used, unless otherwise stated, are branched and unbranched double-bonded alkyl bridges with 1 to 4 carbon atoms which may be mono-, di- or trisubstituted, preferably disubstituted, by a halogen. Accordingly, unless otherwise stated, the term alkylene-OH groups denotes branched and unbranched double-bonded alkyl bridges with 1 to 4 carbon atoms which may be mono-, di- or trisubstituted, preferably monosubstituted, by a hydroxy.

The alkyloxy groups used, unless otherwise stated, are branched and unbranched alkyl groups with 1 to 5 carbon atoms which are linked via an oxygen atom. The following may be mentioned, for example: methyloxy, ethyloxy, propyloxy or butyloxy. The groups methyloxy, ethyloxy, propyloxy or butyloxy may optionally also be referred to by the abbreviations MeO, EtO, PropO or BuO. Unless otherwise stated, the definitions propyloxy and butyloxy also include all possible isomeric forms of the groups in question. Thus, for example, propyloxy includes n-propyloxy and iso-propyloxy, butyloxy includes iso-butyloxy, sec. butyloxy and tert.-butyloxy, etc. The word alkoxy may also possibly be used within the scope of the present invention instead of the word alkyloxy. The groups methyloxy, ethyloxy, propyloxy or butyloxy may optionally also be referred to as methoxy, ethoxy, propoxy or butoxy.

The alkylene-alkyloxy groups used, unless otherwise stated, are branched and unbranched double-bonded alkyl bridges with 1 to 5 carbon atoms which may be mono-, di- or trisubstituted, preferably monosubstituted, by an alkyloxy group.


The -O-CO-alkyl groups used, unless otherwise stated, are branched and unbranched alkyl groups with 1 to 4 carbon atoms which are bonded via an ester group. The alkyl groups are bonded directly to the carbonylcarbon of the ester group. The term -O-CO-alkyl-halogen group should be understood analogously. The group -O-CO-CF_3 denotes trifluoroacetate.

Within the scope of the present invention halogen denotes fluorine, chlorine, bromine or iodine. Unless otherwise stated, fluorine and bromine are the preferred halogens. The group CO denotes a carbonyl group.

The term "therapeutically effective amount" shall mean that amount of a drug or pharmaceutical agent that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by a researcher or clinician.

Within the scope of the present invention, the corticosteroid etiprednol is used together with the abovementioned anticholinergics **1** . Any reference to etiprednol **2** within the scope of the present invention includes a reference to salts or derivatives which may be formed from etiprednol. Examples of possible salts or derivatives include: sodium salts, sulphobenzoates, phosphates, isonicotinates, acetates, propionates, dihydrogen phosphates, palmitates, pivalates or furoates. In some cases etiprednol **2** may also occur in the form of its hydrates.

The compositions according to the invention contain etiprednol preferably in the form of the etiprednol-dichloroacetat (also known in the art as BNP-166) as depicted in formula **2a**



optionally in the form of its enantiomers mixtures of enantiomeres or in the form of the solvates and or hydrates thereof.

It is to be understood that the compositions according to the invention preferably contain only etiprednol **2** in combination with one ore more, preferably one anticholinergic **1** as the only active compounds.

The pharmaceutical combinations of **1** and **2** according to the invention are preferably administered by inhalation. Suitable inhalable powders packed into suitable capsules (inhalettes) may be administered using suitable powder inhalers. Alternatively, the drug may be inhaled by the application of suitable inhalation aerosols. These also include inhalation aerosols which contain HFA134a, HFA227 or a mixture thereof as propellant gas, for example. The drug may also be inhaled using suitable solutions of the pharmaceutical combination consisting of **1** and **2**.

In one aspect, therefore, the invention relates to a pharmaceutical composition which contains a combination of **1** and **2**.

In another aspect the present invention relates to a pharmaceutical composition which contains one or more salts **1** and etiprednol **2**, optionally in the form of their solvates or hydrates. The active substances may be combined in a single preparation or contained in two separate formulations. Pharmaceutical compositions which contain the active substances **1** and **2** in a single preparation are preferred according to the invention.

In another aspect the present invention relates to a pharmaceutical composition which contains, in addition to therapeutically effective quantities of **1** and **2**, a pharmaceutically acceptable excipient. In another aspect the present invention relates to a pharmaceutical composition which does not contain any pharmaceutically acceptable excipient in addition to therapeutically effective quantities of **1** and **2**.

The present invention also relates to the use of **1** and **2** for preparing a pharmaceutical composition containing therapeutically effective quantities of **1** and **2** for treating inflammatory and/or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD), by simultaneous or successive administration. In addition the pharmaceutical combinations according to the invention may be used to prepare a drug for treating cystic fibrosis or allergic alveolitis (farmer's lung), for example, by simultaneous or successive administration. The combinations of active substances according to the

invention will not be used only if treatment with steroids is contraindicated from a therapeutic point of view.

The present invention also relates to the simultaneous or successive use of therapeutically effective doses of the combination of the above pharmaceutical compositions **1** and **2** for treating inflammatory and/or obstructive diseases of the respiratory tract, particularly asthma or chronic obstructive pulmonary disease (COPD), provided that treatment with steroids is not contraindicated from a therapeutic point of view, by simultaneous or successive administration. The invention further relates to the simultaneous or successive use of therapeutically effective doses of the combination of the above pharmaceutical compositions **1** and **2** for treating cystic fibrosis or allergic alveolitis (farmer's lung), for example.

In the active substance combinations of **1** and **2** according to the invention, ingredients **1** and **2** may be present in the form of their enantiomers, mixtures of enantiomers or in the form of racemates.

The proportions in which the active substances **1** and **2** may be used in the active substance combinations according to the invention are variable. Active substances **1** and **2** may possibly be present in the form of their solvates or hydrates. Depending on the choice of the compounds **1** and **2**, the weight ratios which may be used within the scope of the present invention vary on the basis of the different molecular weights of the various compounds and their different potencies. As a rule, the pharmaceutical combinations according to the invention may contain compounds **1** and **2** in ratios by weight ranging from 1:300 to 50:1, preferably from 1:250 to 40:1. In the particularly preferred pharmaceutical combinations which contain tiotropium salt as compound **1** and etiprednol **2** the weight ratios are most preferably in a range in which tiotropium **1'** and **2** are present in ratios of 1:150 to 30:1, more preferably from 1:50 to 20:1.

For example, without restricting the scope of the invention thereto, preferred combinations of **1** and **2** according to the invention may contain tiotropium **1'** and etiprednol **2** in the following proportions by weight: 1:50; 1:49; 1:48; 1:47; 1:46; 1:45; 1:44; 1:43; 1:42; 1:41; 1:40; 1:39; 1:38; 1:37; 1:36; 1:35; 1:34; 1:33; 1:32; 1:31; 1:30; 1:29; 1:28; 1:27; 1:26; 1:25; 1:24; 1:23; 1:22; 1:21; 1:20; 1:19; 1:18; 1:17; 1:16; 1:15; 1:14; 1:13; 1:12; 1:11; 1:10; 1:9; 1:8; 1:7; 1:6; 1:5; 1:4; 1:3; 1:2; 1:1; 2:1; 3:1; 4:1; 5:1; 6:1; 7:1; 8:1; 9:1; 10:1; 11:1; 12:1; 13:1; 14:1; 15:1; 16:1; 17:1; 18:1; 19:1; 20:1.

The pharmaceutical compositions according to the invention containing the combinations of 1 and 2 are normally administered so that 1 and 2 are present together in doses of 1 to 10000μg, preferably from 0.1 to 2000μg, more preferably from 1 to 1000μg, even more preferably from 5 to 500μg, preferably according to the invention from 10 to 300μg, preferably from 20 to 200μg per single dose. For example, combinations of 1 and 2 according to the invention contain a quantity of cation 1' and 2 such that the total dosage per single dose is about 20μg, 25μg, 30μg, 35μg, 45μg, 50μg, 55μg, 60μg, 65μg, 70μg, 75μg, 80μg, 85μg, 90μg, 95μg, 100μg, 105μg, 110μg, 115μg, 120μg, 125μg, 130μg, 135μg, 140μg, 145μg, 150μg, 155μg, 160μg, 165μg, 170μg, 175μg, 180μg, 185μg, 190μg, 195μg, 200μg, 205μg, 210μg, 215μg, 220μg, 225μg, 230μg, 235μg, 240μg, 245μg, 250μg, 255μg, 260μg, 265μg, 270μg, 275μg or the like. In these dosage ranges the active substances 1' and 2 may be present in the weight ratios described above.

For example and without restricting the scope of the invention thereto, the combinations of 1 and 2 according to the invention may contain an amount of cation 1' and etiprednol 2 such that in each single dose 5μg of 1' and 25μg of 2, 5μg of 1' and 50μg of 2, 5μg of 1' and 100μg of 2, 5μg of 1' and 125μg of 2, 5μg of 1' and 200μg of 2, 5μg of 1' and 250μg of 2, 10μg of 1' and 25μg of 2, 10μg of 1' and 50μg of 2, 10μg of 1' and 100μg of 2, 10μg of 1' and 125μg of 2, 10μg of 1' and 200μg of 2, 10μg of 1' and 250μg of 2, 18μg of 1' and 25μg of 2, 18μg of 1' and 50μg of 2, 18μg of 1' and 100μg of 2, 18μg of 1' and 125μg of 2, 18μg of 1' and 200μg of 2, 18μg of 1' and 250μg of 2, 20μg of 1' and 25μg of 2, 20μg of 1' and 50μg of 2, 20μg of 1' and 100μg of 2, 20μg of 1' and 125μg of 2, 20μg of 1' and 200μg of 2, 20μg of 1' and 250μg of 2, 36μg of 1' and 25μg of 2, 36μg of 1' and 50μg of 2, 36μg of 1' and 100μg of 2, 36μg of 1' and 125μg of 2, 36μg of 1' and 200μg of 2, 36μg of 1' and 250μg of 2, 40μg of 1' and 25μg of 2, 40μg of 1' and 50μg of 2, 40μg of 1' and 100μg of 2, 40μg of 1' and 125μg of 2, 40μg of 1' and 200μg of 2 or 40μg of 1' and 250μg of 2 are administered.

The active substance combinations of 1 and 2 according to the invention are preferably administered by inhalation. For this purpose, ingredients 1 and 2 have to be made available in forms suitable for inhalation. Inhalable preparations include inhalable powders, propellant-containing metered-dose aerosols or propellant-free inhalable solutions. Inhalable powders according to the invention containing the combination of active substances 1 and 2 may consist of the active substances on their own or of a mixture of the active substances with physiologically acceptable excipients. Within the scope of the present invention, the term propellant-free inhalable solutions also includes concentrates or sterile inhalable solutions ready for

use. The preparations according to the invention may contain the combination of active substances 1 and 2 either together in one formulation or in two separate formulations. These formulations which may be used within the scope of the present invention are described in more detail in the next part of the specification.

A) Inhalable powder containing the combinations of active substances 1 and 2 according to the invention:

The inhalable powders according to the invention may contain 1 and 2 either on their own or in admixture with suitable physiologically acceptable excipients.

If the active substances 1 and 2 are present in admixture with physiologically acceptable excipients, the following physiologically acceptable excipients may be used to prepare these inhalable powders according to the invention: monosaccharides (e.g. glucose or arabinose), disaccharides (e.g. lactose, saccharose, maltose), oligo- and polysaccharides (e.g. dextran), polyalcohols (e.g. sorbitol, mannitol, xylitol), salts (e.g. sodium chloride, calcium carbonate) or mixtures of these excipients. Preferably, mono- or disaccharides are used, while the use of lactose or glucose is preferred, particularly, but not exclusively, in the form of their hydrates. For the purposes of the invention, lactose is the particularly preferred excipient, while lactose monohydrate is most particularly preferred.

Within the scope of the inhalable powders according to the invention the excipients have a maximum average particle size of up to 250μm, preferably between 10 and 150μm, most preferably between 15 and 80μm. It may sometimes seem appropriate to add finer excipient fractions with an average particle size of 1 to 9μm to the excipient mentioned above. These finer excipients are also selected from the group of possible excipients listed hereinbefore. Finally, in order to prepare the inhalable powders according to the invention, micronised active substance 1 and 2, preferably with an average particle size of 0.5 to 10µm, more preferably from 1 to 5µm, is added to the excipient mixture. Processes for producing the inhalable powders according to the invention by grinding and micronising and by finally mixing the ingredients together are known from the prior art. The inhalable powders according to the invention may be prepared and administered either in the form of a single powder mixture which contains both 1 and 2 or in the form of separate inhalable powders which contain only 1 and 2.

The inhalable powders according to the invention may be administered using inhalers known from the prior art. Inhalable powders according to the invention which contain a physiologically acceptable excipient in addition to 1 and 2 may be administered, for

example, by means of inhalers which deliver a single dose from a supply using a measuring chamber as described in US 4570630A, or by other means as described in DE 36 25 685 A. Preferably, the inhalable powders according to the invention which contain physiologically acceptable excipients in addition to **1** and **2** are packed into capsules (to produce so-called inhalettes) which are used in inhalers as described, for example, in WO 94/28958.

A particularly preferred inhaler for using the pharmaceutical combination according to the invention in inhalettes is shown in Figure 1.

The inhaler according to figure 1 is characterised by a housing 1 containing two windows 2, a deck 3 in which there are air inlet ports and which is provided with a screen 5 secured via a screen housing 4, an inhalation chamber 6 connected to the deck 3 on which there is a push button 9 provided with two sharpened pins 7 and movable counter to a spring 8, a mouthpiece 12 which is connected to the housing 1, the deck 3 and a cover 11 via a spindle 10 to enable it to be flipped open or shut and three holes 13 with diameters below 1 mm in the central region around the capsule chamber 6 and underneath the screen housing 4 and screen 5.
The main air flow enters the inhaler between deck 3 and base 1 near to the hinge. The deck has in this range a reduced width, which forms the entrance slit for the air. Then the flow reverses and enters the capsule chamber 6 through the inlet tube. The flow is then further conducted through the filter and filter holder to the mouthpiece. A small portion of the flow enters the device between mouthpiece and deck and flows then between filterholder and deck into the main stream. Due to production tolerances there is some uncertainty in this flow because of the actual width of the slit between filterholder and deck. In case of new or reworked tools the flow resistance of the inhaler may therefore be a little off the target value. To correct this deviation the deck has in the central region around the capsule chamber 6 and underneath the screen housing 4 and screen 5 three holes 13 with diameters below 1 mm. Through these holes 13 flows air from the base into the main air stream and reduces such slightly the flow resistance of the inhaler. The actual diameter of these holes 13 can be chosen by proper inserts in the tools so that the mean flow resistance can be made equal to the target value.

If the inhalable powders according to the invention are packed into capsules (inhalers) for the preferred use described above, the quantities packed into each capsule should be 1 to 30mg, preferably 3 to 20mg, more particularly 5 to 10mg of inhalable powder per capsule. These capsules contain, according to the invention,

either together or separately, the doses of 1' and 2 mentioned hereinbefore for each single dose.

B) Propellant gas-driven inhalation aerosols containing the combinations of active substances 1 and 2:

Inhalation aerosols containing propellant gas according to the invention may contain substances 1 and 2 dissolved in the propellant gas or in dispersed form. 1 and 2 may be present in separate formulations or in a single preparation, in which 1 and 2 are either each dissolved, dispersed or only one or two of the components is or are dissolved and the other or others is or are dispersed. The propellant gases which may be used to prepare the inhalation aerosols according to the invention are known from the prior art. Suitable propellant gases are selected from among hydrocarbons such as n-propane, n-butane or isobutane and halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane. The propellant gases mentioned above may be used on their own or in mixtures thereof. Particularly preferred propellant gases are halogenated alkane derivatives selected from TG134a (1,1,1,2-tetrafluoroethane) and TG227 (1,1,1,2,3,3,3-heptafluoropropane) and mixtures thereof.

The propellant-driven inhalation aerosols according to the invention may also contain other ingredients such as co-solvents, stabilisers, surfactants, antioxidants, lubricants and pH adjusters. All these ingredients are known in the art.

The inhalation aerosols containing propellant gas according to the invention may contain up to 5 wt.-% of active substance 1 and/or 2. Aerosols according to the invention contain, for example, 0.002 to 5 wt.-%, 0.01 to 3 wt.-%, 0.015 to 2 wt.-%, 0.1 to 2 wt.-%, 0.5 to 2 wt.-% or 0.5 to 1 wt.-% of active substance 1 and/or 2.

If the active substances 1 and/or 2 are present in dispersed form, the particles of active substance preferably have an average particle size of up to 10μm, preferably from 0.1 to 5μm, more preferably from 1 to 5μm.

The propellant-driven inhalation aerosols according to the invention mentioned above may be administered using inhalers known in the art (MDIs = metered dose inhalers). Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of propellant-driven aerosols as hereinbefore described combined with one or more inhalers suitable for administering these aerosols. In addition, the present invention relates to inhalers which are characterised in that they contain the propellant gas-containing aerosols described above according to the

invention. The present invention also relates to cartridges which are fitted with a suitable valve and can be used in a suitable inhaler and which contain one of the above-mentioned propellant gas-containing inhalation aerosols according to the invention. Suitable cartridges and methods of filling these cartridges with the inhalable aerosols containing propellant gas according to the invention are known from the prior art.

C) Propellant-free inhalable solutions or suspensions containing the combinations of active substances 1 and 2 according to the invention:

It is particularly preferred to use the active substance combination according to the invention in the form of propellant-free inhalable solutions and suspensions. The solvent used may be an aqueous or alcoholic, preferably an ethanolic solution. The solvent may be water on its own or a mixture of water and ethanol. The relative proportion of ethanol compared with water is not limited but the maximum is up to 70 percent by volume, more particularly up to 60 percent by volume and most preferably up to 30 percent by volume. The remainder of the volume is made up of water. The solutions or suspensions containing 1 and 2, separately or together, are adjusted to a pH of 2 to 7, preferably 2 to 5, using suitable acids. The pH may be adjusted using acids selected from inorganic or organic acids. Examples of suitable inorganic acids include hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid and/or phosphoric acid. Examples of particularly suitable organic acids include ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and/or propionic acid etc. Preferred inorganic acids are hydrochloric and sulphuric acids. It is also possible to use the acids which have already formed an acid addition salt with one of the active substances. Of the organic acids, ascorbic acid, fumaric acid and citric acid are preferred. If desired, mixtures of the above acids may be used, particularly in the case of acids which have other properties in addition to their acidifying qualities, e.g. as flavourings, antioxidants or complexing agents, such as citric acid or ascorbic acid, for example. According to the invention, it is particularly preferred to use hydrochloric acid to adjust the pH.

According to the invention, the addition of editic acid (EDTA) or one of the known salts thereof, sodium edetate, as stabiliser or complexing agent is unnecessary in the present formulation. Other embodiments may contain this compound or these compounds. In a preferred embodiment the content based on sodium edetate is less than 100 mg/100ml, preferably less than 50mg/100ml, more preferably less than 20mg/100ml. Generally, inhalable solutions in which the content of sodium edetate is from 0 to 10mg/100ml are preferred.

Co-solvents and/or other excipients may be added to the propellant-free inhalable solutions according to the invention. Preferred co-solvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols - particularly isopropyl alcohol, glycols - particularly propyleneglycol, polyethyleneglycol, polypropyleneglycol, glycolether, glycerol, polyoxyethylene alcohols and polyoxyethylene fatty acid esters. The terms excipients and additives in this context denote any pharmacologically acceptable substance which is not an active substance but which can be formulated with the active substance or substances in the physiologically suitable solvent in order to improve the qualitative properties of the active substance formulation. Preferably, these substances have no pharmacological effect or, in connection with the desired therapy, no appreciable or at least no undesirable pharmacological effect. The excipients and additives include, for example, surfactants such as soya lecithin, oleic acid, sorbitan esters, such as polysorbates, polyvinylpyrrolidone, other stabilisers, complexing agents, antioxidants and/or preservatives which guarantee or prolong the shelf life of the finished pharmaceutical formulation, flavourings, vitamins and/or other additives known in the art. The additives also include physiologically acceptable salts such as sodium chloride as isotonic agents.

The preferred excipients include antioxidants such as ascorbic acid, for example, provided that it has not already been used to adjust the pH, vitamin A, vitamin E, tocopherols and similar vitamins and provitamins occurring in the human body.

Preservatives may be used to protect the formulation from contamination with pathogens. Suitable preservatives are those which are known in the art, particularly cetyl pyridinium chloride, benzalkonium chloride or benzoic acid or benzoates such as sodium benzoate in the concentration known from the prior art. The preservatives mentioned above are preferably present in concentrations of up to 50mg/100ml, more preferably between 5 and 20mg/100ml.

Preferred formulations contain, in addition to the solvent water and the combination of active substances **1** and **2**, only benzalkonium chloride and sodium edetate. In another preferred embodiment, no sodium edetate is present.

The propellant-free inhalable solutions according to the invention are administered in particular using inhalers of the kind which are capable of nebulising a small amount of a liquid formulation in the required therapeutic dose within a few seconds to produce an aerosol suitable for therapeutic inhalation. Within the scope of the present invention, preferred nebulisers are those in which a quantity of less than 100µL, preferably less than 50µL, more preferably between 10 and 30µL of active

substance solution can be nebulised in preferably one spray action to form an aerosol with an average particle size of less than 20µm, preferably less than 10µm, in such a way that the inhalable part of the aerosol corresponds to the therapeutically effective quantity.

An apparatus of this kind for propellant-free delivery of a metered quantity of a liquid pharmaceutical composition for inhalation is described for example in International Patent Application WO 91/14468 and also in WO 97/12687 (cf. in particular Figures 6a and 6b). The nebulisers (devices) described therein are known by the name Respimat®.

This nebuliser (Respimat®) can advantageously be used to produce the inhalable aerosols according to the invention containing the combination of active substances **1** and **2**. Because of its cylindrical shape and handy size of less than 9 to 15 cm long and 2 to 4 cm wide, this device can be carried at all times by the patient. The nebuliser sprays a defined volume of pharmaceutical formulation using high pressures through small nozzles so as to produce inhalable aerosols.

The preferred atomiser essentially consists of an upper housing part, a pump housing, a nozzle, a locking mechanism, a spring housing, a spring and a storage container, characterised by

- a pump housing which is secured in the upper housing part and which comprises at one end a nozzle body with the nozzle or nozzle arrangement,
- a hollow plunger with valve body,
- a power takeoff flange in which the hollow plunger is secured and which is located in the upper housing part,
- a locking mechanism situated in the upper housing part,
- a spring housing with the spring contained therein, which is rotatably mounted on the upper housing part by means of a rotary bearing,
- a lower housing part which is fitted onto the spring housing in the axial direction.

The hollow plunger with valve body corresponds to a device disclosed in WO 97/12687. It projects partially into the cylinder of the pump housing and is axially movable within the cylinder. Reference is made in particular to Figures 1 to 4, especially Figure 3, and the relevant parts of the description. The hollow plunger with valve body exerts a pressure of 5 to 60 Mpa (about 50 to 600 bar), preferably 10 to 60 Mpa (about 100 to 600 bar) on the fluid, the measured amount of active substance solution, at its high pressure end at the moment when the spring is

actuated. Volumes of 10 to 50 microlitres are preferred, while volumes of 10 to 20 microlitres are particularly preferred and a volume of 15 microlitres per spray is most particularly preferred.

The valve body is preferably mounted at the end of the hollow plunger facing the valve body.

The nozzle in the nozzle body is preferably microstructured, i.e. produced by microtechnology. Microstructured nozzle bodies are disclosed for example in WO-94/07607; reference is hereby made to the contents of this specification, particularly Figure 1 therein and the associated description.
The nozzle body consists for example of two sheets of glass and/or silicon firmly joined together, at least one of which has one or more microstructured channels which connect the nozzle inlet end to the nozzle outlet end. At the nozzle outlet end there is at least one round or non-round opening 2 to 10 microns deep and 5 to 15 microns wide, the depth preferably being 4.5 to 6.5 microns while the length is preferably 7 to 9 microns.
In the case of a plurality of nozzle openings, preferably two, the directions of spraying of the nozzles in the nozzle body may extend parallel to one another or may be inclined relative to one another in the direction of the nozzle opening. In a nozzle body with at least two nozzle openings at the outlet end the directions of spraying may be at an angle of 20 to 160° to one another, preferably 60 to 150°, most preferably 80 to 100°. The nozzle openings are preferably arranged at a spacing of 10 to 200 microns, more preferably at a spacing of 10 to 100 microns, most preferably 30 to 70 microns. Spacings of 50 microns are most preferred. The directions of spraying will therefore meet in the vicinity of the nozzle openings.

The liquid pharmaceutical preparation strikes the nozzle body with an entry pressure of up to 600 bar, preferably 200 to 300 bar, and is atomised into an inhalable aerosol through the nozzle openings. The preferred particle or droplet sizes of the aerosol are up to 20 microns, preferably 3 to 10 microns.

The locking mechanism contains a spring, preferably a cylindrical helical compression spring, as a store for the mechanical energy. The spring acts on the power takeoff flange as an actuating member the movement of which is determined by the position of a locking member. The travel of the power takeoff flange is precisely limited by an upper and lower stop. The spring is preferably biased, via a power step-up gear, e.g. a helical thrust gear, by an external torque which is

produced when the upper housing part is rotated counter to the spring housing in the lower housing part. In this case, the upper housing part and the power takeoff flange have a single or multiple V-shaped gear.

The locking member with engaging locking surfaces is arranged in a ring around the power takeoff flange. It consists, for example, of a ring of plastic or metal which is inherently radially elastically deformable. The ring is arranged in a plane at right angles to the atomiser axis. After the biasing of the spring, the locking surfaces of the locking member move into the path of the power takeoff flange and prevent the spring from relaxing. The locking member is actuated by means of a button. The actuating button is connected or coupled to the locking member. In order to actuate the locking mechanism, the actuating button is moved parallel to the annular plane, preferably into the atomiser; this causes the deformable ring to deform in the annular plane. Details of the construction of the locking mechanism are given in WO 97/20590.

The lower housing part is pushed axially over the spring housing and covers the mounting, the drive of the spindle and the storage container for the fluid.

When the atomiser is actuated the upper housing part is rotated relative to the lower housing part, the lower housing part taking the spring housing with it. The spring is thereby compressed and biased by means of the helical thrust gear and the locking mechanism engages automatically. The angle of rotation is preferably a whole-number fraction of 360 degrees, e.g. 180 degrees. At the same time as the spring is biased, the power takeoff part in the upper housing part is moved along by a given distance, the hollow plunger is withdrawn inside the cylinder in the pump housing, as a result of which some of the fluid is sucked out of the storage container and into the high pressure chamber in front of the nozzle.

If desired, a number of exchangeable storage containers which contain the fluid to be atomised may be pushed into the atomiser one after another and used in succession. The storage container contains the aqueous aerosol preparation according to the invention.

The atomising process is initiated by pressing gently on the actuating button. As a result, the locking mechanism opens up the path for the power takeoff member. The biased spring pushes the plunger into the cylinder of the pump housing. The fluid leaves the nozzle of the atomiser in atomised form.

Further details of construction are disclosed in PCT Applications WO 97/12683 and WO 97/20590, to which reference is hereby made.

The components of the atomiser (nebuliser) are made of a material which is suitable for its purpose. The housing of the atomiser and, if its operation permits, other parts as well, are preferably made of plastics, e.g. by injection moulding. For medicinal purposes, physiologically safe materials are used.

Figures 6a/b of WO 97/12687, which are specifically incorporated by reference into the instant application show the nebuliser (Respimat®) which can advantageously be used for inhaling the aqueous aerosol preparations according to the invention.

Figure 6a of WO 97/12687 shows a longitudinal section through the atomiser with the spring biased while Figure 6b of WO 97/12687 shows a longitudinal section through the atomiser with the spring relaxed. The upper housing part (51) contains the pump housing (52) on the end of which is mounted the holder (53) for the atomiser nozzle. In the holder is the nozzle body (54) and a filter (55). The hollow plunger (57) fixed in the power takeoff flange (56) of the locking mechanism projects partially into the cylinder of the pump housing. At its end the hollow plunger carries the valve body (58). The hollow plunger is sealed off by means of the seal (59). Inside the upper housing part is the stop (60) on which the power takeoff flange abuts when the spring is relaxed. On the power takeoff flange is the stop (61) on which the power takeoff flange abuts when the spring is biased. After the biasing of the spring the locking member (62) moves between the stop (61) and a support (63) in the upper housing part. The actuating button (64) is connected to the locking member. The upper housing part ends in the mouthpiece (65) and is sealed off by means of the protective cover (66) which can be placed thereon.

The spring housing (67) with compression spring (68) is rotatably mounted on the upper housing part by means of the snap-in lugs (69) and rotary bearing. The lower housing part (70) is pushed over the spring housing. Inside the spring housing is the exchangeable storage container (71) for the fluid (72) which is to be atomised. The storage container is sealed off by the stopper (73) through which the hollow plunger projects into the storage container and is immersed at its end in the fluid (supply of active substance solution).

The spindle (74) for the mechanical counter is mounted in the covering of the spring housing. At the end of the spindle facing the upper housing part is the drive pinion (75). The slider (76) sits on the spindle.

The nebuliser described above is suitable for nebulising the aerosol preparations according to the invention to produce an aerosol suitable for inhalation.

If the formulation according to the invention is nebulised using the method described above (Respimat®) the quantity delivered should correspond to a defined quantity with a tolerance of not more than 25%, preferably 20% of this amount in at least 97%, preferably at least 98% of all operations of the inhaler (spray actuations). Preferably, between 5 and 30 mg of formulation, most preferably between 5 and 20 mg of formulation are delivered as a defined mass on each actuation.

However, the formulation according to the invention may also be nebulised by means of inhalers other than those described above, e.g. jet stream inhalers or other stationary nebulisers.

Accordingly, in a further aspect, the invention relates to pharmaceutical formulations in the form of propellant-free inhalable solutions or suspensions as described above combined with a device suitable for administering these formulations, preferably in conjunction with the Respimat®. Preferably, the invention relates to propellant-free inhalable solutions or suspensions characterised by the combination of active substances **1** and **2** according to the invention in conjunction with the device known by the name Respimat®. In addition, the present invention relates to the above-mentioned devices for inhalation, preferably the Respimat®, characterised in that they contain the propellant-free inhalable solutions or suspensions according to the invention as described hereinbefore.

The propellant-free inhalable solutions or suspensions according to the invention may take the form of concentrates or sterile inhalable solutions or suspensions ready for use, as well as the above-mentioned solutions and suspensions designed for use in a Respimat®. Formulations ready for use may be produced from the concentrates, for example, by the addition of isotonic saline solutions. Sterile formulations ready for use may be administered using energy-operated fixed or portable nebulisers which produce inhalable aerosols by means of ultrasound or compressed air by the Venturi principle or other principles.

Accordingly, in another aspect, the present invention relates to pharmaceutical compositions in the form of propellant-free inhalable solutions or suspensions as described hereinbefore which take the form of concentrates or sterile formulations ready for use, combined with a device suitable for administering these solutions, characterised in that the device is an energy-operated free-standing or portable

nebuliser which produces inhalable aerosols by means of ultrasound or compressed air by the Venturi principle or other methods.

The Examples which follow serve to illustrate the present invention in more detail without restricting the scope of the invention to the following embodiments by way of example.

Examples of Formulations

A) Inhalable powders:

Ingredients	µg per capsule
tiotropium bromide monohydrate	22.5
etiprednol-dichloroacetate	250
lactose	4727.5
Total	5000

Ingredients	µg per capsule
tiotropium bromide	21.7
etiprednol-dichloroacetate	250
lactose	4728.3
Total	5000

Ingredients	µg per capsule
tropenol 2,2-diphenylpropionic acid ester methobromide	100
etiprednol-dichloroacetate	200
lactose	4700
Total	5000

Ingredients	µg per capsule
tropenol 2,2-diphenylpropionic acid ester methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	µg per capsule
scopine 9-methyl-xanthene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	200
lactose	4700
Total	5000

Ingredients	µg per capsule
tropenol 9-methyl-fluorene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	200
lactose	4700
Total	5000

Ingredients	µg per capsule
tropenol 9-methyl-fluorene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	µg per capsule
scopine 9-methyl-fluorene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	200
lactose	4700
Total	5000

5

Ingredients	µg per capsule
scopine 9-methyl-fluorene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	µg per capsule
cyclopropyltropine 2,2-diphenylpropionate methobromide	100
etiprednol-dichloroacetate	200
lactose	4700

Total	5000

Ingredients	µg per capsule
cyclopropyltropine 2,2-diphenylpropionate methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	µg per capsule
cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	200
lactose	4700
Total	5000

5

Ingredients	µg per capsule
cyclopropyltropine 9-hydroxy-fluorene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	µg per capsule
tropenol 9-methyl-xanthene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	µg per capsule
tropenol 9-methyl-xanthene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	200

lactose	4700
Total	5000

Ingredients	**µg per capsule**
scopine 9-methyl-xanthene-9-carboxylate methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

Ingredients	**µg per capsule**
scopine 2,2-diphenylpropionic acid ester methobromide	100
etiprednol-dichloroacetate	200
lactose	4700
Total	5000

Ingredients	**µg per capsule**
scopine 2,2-diphenylpropionic acid ester methobromide	100
etiprednol-dichloroacetate	250
lactose	4650
Total	5000

5

B) Inhalable aerosols containing propellant gas:

Ingredients	**Wt-%**
tiotropium bromide	0.029
etiprednol-dichloroacetate	0.4
isopropyl myristate	0.1
TG227	ad 100

Ingredients	**% by weight**
tropenol 2,2-diphenylpropionic acid ester methobromide	0.020

etiprednol-dichloroacetate	0.4
soya lecithin	0.2
TG 134a : TG227 = 2:3	ad 100

Ingredients	**% by weight**
tropenol 2,2-diphenylpropionic acid ester methobromide	0.020
etiprednol-dichloroacetate	0.3
Isopropyl myristate	0.1
TG 227	ad 100

Ingredients	**% by weight**
scopine 2,2-diphenylpropionic acid ester methobromide	0.020
etiprednol-dichloroacetate	0.4
soya lecithin	0.2
TG 134a : TG227 = 2:3	ad 100

Ingredients	**% by weight**
scopine 2,2-diphenylpropionic acid ester methobromide	0.020
etiprednol-dichloroacetate	0.3
Isopropyl myristate	0.1
TG 227	ad 100

5

Patent Claims


1) Pharmaceutical composition, characterised in that it contains one or more anticholinergics (**1**) in conjunction with etiprednol (**2**), optionally in the form of the enantiomers, mixtures of the enantiomers or in the form of the racemates thereof, optionally in the form of the solvates or hydrates and optionally together with a pharmaceutically acceptable excipient.

2) Pharmaceutical composition according to claim 1, characterised in that the active substances **1** and **2** are present either together in a single formulation or in two separate formulations.

3) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the group consisting of tiotropium salts, oxitropium salts or ipratropium salts, preferably tiotropium salts.

4) Pharmaceutical composition according to one of claims 1 to 3, characterised in that **1** is present in the form of the chloride, bromide, iodide, methanesulphonate, sulphate or paratoluene sulphonate, preferably in the form of the bromide.


5) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the compounds of formula **1a**



1a

wherein

A denotes a double-bonded group selected from among



;

X^- may have the meanings as mentioned hereinbefore, preferably chloride, bromide or methansulphonate,

R^1 and R^2 which may be identical or different denote a group selected from among

methyl, ethyl, n-propyl and iso-propyl, which may optionally be substituted by hydroxy or fluorine, preferably unsubstituted methyl;


R^3, R^4, R^5 and R^6, which may be identical or different, denote hydrogen, methyl, ethyl,

methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF_3 or NO_2;

R^7 denotes hydrogen, methyl, ethyl, methyloxy, ethyloxy, $-CH_2-F$, $-CH_2-CH_2-F$, $-O-CH_2-F$, $-O-CH_2-CH_2-F$, $-CH_2-OH$, $-CH_2-CH_2-OH$, CF_3, $-CH_2-OMe$, $-CH_2-CH_2-OMe$, $-CH_2-OEt$, $-CH_2-CH_2-OEt$, -O-COMe, -O-COEt, $-O-COCF_3$, $-O-COCF_3$, fluorine, chlorine or bromine,

optionally together with a pharmaceutically acceptable excipient..

6) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the compounds of formula **1b**



1b

wherein


A, X^-, R^1 and R^2 may have the meanings according to claim 5;

R^7, R^8, R^9, R^{10}, R^{11} and R^{12} , which may be identical or different, denote hydrogen, methyl, ethyl, methyloxy, ethyloxy, hydroxy, fluorine, chlorine, bromine, CN, CF_3 or NO_2, with the proviso that at least one of the groups R^7, R^8, R^9, R^{10}, R^{11} and R^{12} is not hydrogen,

optionally together with a pharmaceutically acceptable excipient.

7) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the compounds of formula **1c**

35



1c

wherein A and X⁻ may have the meanings according to claim 5;

R^{15} denotes hydrogen, hydroxy, methyl, ethyl, $-CF_3$, CHF_2 or fluorine;

$R^{1'}$ and $R^{2'}$ which may be identical or different denote C_1-C_5-alkyl which may optionally be substituted by C_3-C_6-cycloalkyl, hydroxy or halogen,


or

$R^{1'}$ and $R^{2'}$ together denote a -C_3-C_5-alkylene-bridge;

R^{13}, R^{14}, $R^{13'}$ and $R^{14'}$ which may be identical or different denote hydrogen, -C_1-C_4-alkyl, -C_1-C_4-alkyloxy, hydroxy, $-CF_3$, $-CHF_2$, CN, NO_2 or halogen,

optionally together with a pharmaceutically acceptable excipient.

8) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the compounds of formula **1d**



1d

wherein X⁻ may have the meanings according to claim 5,

D and B which may be identical or different, preferably identical, denote -O, -S, -NH, $-CH_2$, -CH=CH, or -N(C_1-C_4-alkyl)-;

R^{16} denotes hydrogen, hydroxy, -C_1-C_4-alkyl, -C_1-C_4-alkyloxy, -C_1-C_4-alkylene-Halogen, -O-C_1-C_4-alkylene-halogen,

$-C_1$-C_4-alkylene-OH, $-CF_3$, CHF_2, $-C_1$-C_4-alkylene-C_1-C_4-alkyloxy, $-O-COC_1$-C_4-alkyl, $-O-COC_1$-C_4-alkylene-halogen, $-C_1$-C_4-alkylene-C_3-C_6-cycloalkyl, $-O-COCF_3$ or halogen;

$R^{1''}$ and $R^{2''}$ which may be identical or different, denote $-C_1$-C_5-alkyl, which may optionally be substituted by $-C_3$-C_6-cycloalkyl, hydroxy or halogen,

or

$R^{1''}$ and $R^{2''}$ together denote a $-C_3$-C_5-alkylene bridge;

R^{17}, R^{18}, $R^{17'}$ and $R^{18'}$, which may be identical or different, denote hydrogen, C_1-C_4-alkyl, C_1-C_4-alkyloxy, hydroxy, $-CF_3$, $-CHF_2$, CN, NO_2 or halogen;


R^X and $R^{X'}$ which may be identical or different, denote hydrogen, C_1-C_4-alkyl, C_1-C_4-alkyloxy, hydroxy, $-CF_3$, $-CHF_2$, CN, NO_2 or halogen

or

R^X and $R^{X'}$ together denote a single bond or a bridging group selected from among the bridges -O, -S, -NH, $-CH_2$, $-CH_2-CH_2-$, $-N(C_1$-C_4-alkyl), $-CH(C_1$-C_4-alkyl)- and $-C(C_1$-C_4-alkyl$)_2$,

optionally together with a pharmaceutically acceptable excipient.



9) Pharmaceutical composition according to one of claims 1 and 2, characterised in that **1** is selected from the compounds of formula **1e**



1e

wherein X^- may have the meanings according to claim 5;

A' denotes a double-bonded group selected from among

 and  ;

R^{19} denotes hydroxy, methyl, hydroxymethyl, ethyl, $-CF_3$, CHF_2 or fluorine;

$R^{1'''}$ and $R^{2'''}$ which may be identical or different denote C_1-C_5-alkyl which may optionally be substituted by C_3-C_6-cycloalkyl, hydroxy or halogen,

or

$R^{1'''}$ and $R^{2'''}$ together denote a $-C_3$-C_5-alkylene-bridge;

R^{20}, R^{21}, $R^{20'}$ and $R^{21'}$ which may be identical or different denote hydrogen, $-C_1$-C_4-alkyl, $-C_1$-C_4-alkyloxy, hydroxy, $-CF_3$, $-CHF_2$, CN, NO_2 or halogen,

optionally together with a pharmaceutically acceptable excipient.

10) Pharmaceutical compositions according to one of claims 1 to 9, characterised in that the weight ratios of **1** to **2** are in the range from 1:300 to 50:1, preferably from 1:250 to 40:1.

11) Pharmaceutical composition according to one of claims 1 to 10, characterised in that a single administration corresponds to a dose of the active substance combination **1** and **2** of 0.01 to 10,000μg, preferably from 0.1 to 2000μg.

12) Pharmaceutical composition according to one of claims 1 to 11, characterised in that it is in the form of a formulation suitable for inhalation.

13) Pharmaceutical composition according to claim 12, characterised in that it is a formulation selected from among inhalable powders, propellant-containing metered-dose aerosols and propellant-free inhalable solutions or suspensions.

14) Pharmaceutical composition according to claim 13, characterised in that it is an inhalable powder which contains **1** and **2** in admixture with suitable physiologically acceptable excipients selected from among the monosaccharides, disaccharides, oligo- and polysaccharides, polyalcohols, salts, or mixtures of these excipients.

15) Inhalable powder according to claim 14, characterised in that the excipient has a maximum average particle size of up to 250µm, preferably between 10 and 150µm.

16) Capsules, characterised in that they contain an inhalable powder according to claim 14 or 15.

17) Pharmaceutical composition according to claim 13, characterised in that it is an inhalable powder which contains only the active substances **1** and **2** as its ingredients.

18) Pharmaceutical composition according to claim 13, characterised in that it is a propellant-containing inhalable aerosol which contains **1** and **2** in dissolved or dispersed form.

19) Propellant-containing inhalable aerosol according to claim 18, characterised in that it contains, as propellant gas, hydrocarbons such as n-propane, n-butane or isobutane or halohydrocarbons such as fluorinated derivatives of methane, ethane, propane, butane, cyclopropane or cyclobutane.

20) Propellant-containing inhalable aerosol according to claim 19, characterised in that the propellant gas is TG134a, TG227 or a mixture thereof.

21) Propellant-containing inhalable aerosol according to claim 18, 19 or 20, characterised in that it optionally contains one or more other ingredients selected from among cosolvents, stabilisers, surfactants, antioxidants, lubricants and means for adjusting the pH.

22) Propellant-containing inhalable aerosol according to one of claims 18 to 21, characterised in that it may contain up to 5 wt.-% of active substance **1** and/or **2**.

23) Pharmaceutical composition according to claim 13, characterised in that it is a propellant-free inhalable solution or suspension which contains water, ethanol or a mixture of water and ethanol as solvent.

24) Inhalable solution or suspension according to claim 23, characterised in that the pH is 2 - 7, preferably 2 -5.

25) Inhalable solution or suspension according to claim 24, characterised in that the pH is adjusted by means of an acid selected from among hydrochloric acid, hydrobromic acid, nitric acid, sulphuric acid, ascorbic acid, citric acid, malic acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid and propionic acid or mixtures thereof.

26) Inhalable solution or suspension according to one of claims 13 to 25, characterised in that it optionally contains other co-solvents and/or excipients.

27) Use of a composition according to one of claims 1 to 26 for preparing a medicament for treating inflammatory or obstructive diseases of the respiratory tract.




FIG. 1.

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/050901

A. CLASSIFICATION OF SUBJECT MATTER
INV. A61K31/573 A61K31/46 A61P11/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
EPO-Internal, EMBASE, WPI Data, PAJ, BIOSIS, CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	WO 2005/020963 A (IVAX CORPORATION; NORTON HEALTH CARE LTD; XIAN-MING, ZENG; SEAN, KEE T) 10 March 2005 (2005-03-10) page 8, paragraph 34-36	1-4, 10-27
P,Y	page 9, paragraph 42	5-9
Y	KURUCZ I ET AL: "Potency and specificity of the pharmacological action of a new, antiasthmatic, topically administered soft steroid, etiprednol dicloacetate (BNP-166)" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS 01 OCT 2003 UNITED STATES, vol. 307, no. 1, 1 October 2003 (2003-10-01), pages 83-92, XP002378252 ISSN: 0022-3565 the whole document	1-27

-/--

[X] Further documents are listed in the continuation of Box C.

[X] See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
25 April 2006	18/05/2006

Name and mailing address of the ISA/	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL – 2280 HV Rijswijk Tel. (+31–70) 340–2040, Tx. 31 651 epo nl, Fax: (+31–70) 340–3016	Collura, A

3

Form PCT/ISA/210 (second sheet) (April 2005)

INTERNATIONAL SEARCH REPORT

International application No
PCT/EP2006/050901

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	WO 02/32899 A (BOEHRINGER INGELHEIM PHARMA KG; MEISSNER, HELMUT; MORSCHHAEUSER, GERD;) 25 April 2002 (2002-04-25) cited in the application page 24, last paragraph - page 25, paragraph 2	1-5, 10-27
Y	WO 02/32898 A (BOEHRINGER INGELHEIM PHARMA KG; MEISSNER, HELMUT; MORSCHHAEUSER, GERD;) 25 April 2002 (2002-04-25) cited in the application page 49, last paragraph - page 50, paragraph 2	1-4,6, 10-27
Y	WO 03/064419 A (BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG; PESTEL, SABINE; REICHL, RIC) 7 August 2003 (2003-08-07) cited in the application page 15, last paragraph - page 16, paragraph 2	1-4,7, 10-27
Y	WO 03/064418 A (BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG; SPECK, GEORG; EICKMEIER, CH) 7 August 2003 (2003-08-07) page 22, last paragraph - page 23, paragraph 2	1-4,8, 10-27
Y	WO 03/064417 A (BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG; PESTEL, SABINE; REICHL, RIC) 7 August 2003 (2003-08-07) cited in the application page 18, paragraph 4 - page 19, paragraph 1	1-4,9-27
P,A	WO 2005/102349 A (BOEHRINGER INGELHEIM INTERNATIONAL GMBH; BOEHRINGER INGELHEIM PHARMA G) 3 November 2005 (2005-11-03) claims 7,11-15,19	1-27

3

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2006/050901

Patent document cited in search report	.	Publication date	Patent family member(s)		Publication date
WO 2005020963	A	10-03-2005	NONE		
WO 0232899	A	25-04-2002	AT	259805 T	15-03-2004
			AU	1397502 A	29-04-2002
			BG	107688 A	30-09-2003
			BR	0114635 A	10-02-2004
			CA	2425557 A1	11-04-2003
			CN	1468236 A	14-01-2004
			DE	10050994 A1	18-04-2002
			DK	1325001 T3	21-06-2004
			EA	5816 B1	30-06-2005
			EE	200300151 A	16-06-2003
			EP	1325001 A1	09-07-2003
			ES	2215147 T3	01-10-2004
			HR	20030278 A2	28-02-2005
			HU	0301203 A2	28-10-2003
			JP	2004511557 T	15-04-2004
			MX	PA03003160 A	09-09-2005
			NO	20031693 A	28-05-2003
			NZ	525836 A	24-09-2004
			PL	360673 A1	20-09-2004
			PT	1325001 T	30-07-2004
			SK	4352003 A3	05-08-2003
			TR	200400376 T4	22-03-2004
			UA	73804 C2	15-08-2003
			ZA	200302914 A	14-11-2003
WO 0232898	A	25-04-2002	AU	1397702 A	29-04-2002
			CA	2425560 A1	11-04-2003
			DE	10050995 A1	18-04-2002
			EP	1328524 A2	23-07-2003
			JP	2004511556 T	15-04-2004
			MX	PA03003093 A	30-06-2005
WO 03064419	A	07-08-2003	AT	299880 T	15-08-2005
			BR	0307294 A	21-12-2004
			CA	2472149 A1	07-08-2003
			CN	1625557 A	08-06-2005
			DE	10203741 A1	14-08-2003
			EP	1472251 A1	03-11-2004
			ES	2245443 T3	01-01-2006
			HR	20040690 A2	31-10-2005
			JP	2005516067 T	02-06-2005
			MX	PA04007245 A	29-10-2004
			NZ	534784 A	26-08-2005
			PT	1472251 T	31-10-2005
			ZA	200404366 A	05-07-2005
WO 03064418	A	07-08-2003	BR	0307299 A	21-12-2004
			CA	2474874 A1	07-08-2003
			CN	1625556 A	08-06-2005
			DE	10203749 A1	14-08-2003
			EP	1472250 A1	03-11-2004
			JP	2005525323 T	25-08-2005
			MX	PA04007249 A	29-10-2004
WO 03064417	A	07-08-2003	CA	2471578 A1	07-08-2003
			DE	10203753 A1	14-08-2003

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No
PCT/EP2006/050901

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 03064417 A		EP 1472249 A1	03-11-2004
		JP 2005525322 T	25-08-2005
WO 2005102349 A	03-11-2005	NONE	